- LexaGene (LXG) has received purchase orders for the MiQLab System from two private veterinary clinics
- The MiQLab System provides rapid testing for pathogens and markers of antibiotic resistance so that veterinarians can make fast, evidence-based treatment decisions
- LexaGene develops fully automated, rapid molecular testing for accurate pathogen detection in human and veterinary diagnostics
- LexaGene Holdings Inc. (LXG) opened trading at C$0.46 per share
LexaGene (LXG) has received purchase orders from Kuma Veterinary Clinic and the Emergency Veterinary Services of Roanoke.
Dr. Jack Regan, LexaGene’s Founder and CEO commented,
“I’m pleased to announce that we have closed additional MiQLab System sales to private hospitals. Veterinarians are learning more about our system and recognizing how wrong it is to have to wait days to weeks for a reference lab to provide infectious disease results that can impact the well-being of their patients. Our MiQLab System provides them a solution to this problem, as it delivers high-quality results at the point of need in just ~2 hours. This time savings empowers them to make evidence-based decisions to improve the quality of the care they provide.”
Gwyneth Shugart, CVT and co-owner of Kuma Veterinary Clinic added,
“We purchased the MiQLab system to offer better services to our clients and the pets they love. Too often, slow diagnostics have prevented us from more rapidly improving our patients’ health, which has led to frustration, unnecessary pain and suffering, and higher costs. It is truly exciting to have this new diagnostic in our hospital, as we put the days of practicing medicine based on empiric diagnosis behind us.”
LexaGene’s MiQLab System provides rapid testing for pathogens and markers of antibiotic resistance so that veterinarians can make fast, evidence-based treatment decisions.
LexaGene Holdings Inc. is a molecular diagnostics company that develops systems for on-site rapid testing in veterinary diagnostics, food safety, clinical research, agricultural testing, and biodefense.
LexaGene Holdings Inc. (LXG) opened trading at C$0.46 per share.
